Injectable Drug Delivery Market Size, Share, Opportunities, And Trends By Device Type (Needle-free injectors, Patch injectors, Auto injectors, Others), By Application (Disease Treatment, Research/Academic purposes), And By Geography - Forecasts From 2025 To 2030

The injectable drug delivery market is projected to grow at a CAGR of 12.06% to reach US$ 804.844 billion by 2024. 

Injectable drug delivery is considered to be the most effective means of drug delivery into the human body and is thus considered to be the most effective administration route. These are in high demand due to the prevalence of chronic diseases worldwide driving the market growth during the forecast period. Furthermore, growing R&D activities, growing health expenditure and growing age-related diseases with the increasing elderly population worldwide are also driving the growth of the global injectable drug delivery market in the forecast period.

DRIVERS

Prevalence of chronic diseases worldwide.

Increasing health expenditure worldwide.

Growing geriatric population.

RESTRAINTS

Stringent regulations regarding approval of drugs and medical devices.

INDUSTRY UPDATE

On May 2, 2018, Haselmeier which is a Swiss-based developer and manufacturer of innovative self-injection devices announced that it has entered into a partnership agreement with the Common sensing which is a Cambridge-based smart injector monitoring and support solutions company. The partnership is for the development of smart connected monitoring and support solutions for the patients using injectable medicines.

On July 26, 2018, Merck and InnoCore Pharmaceuticals entered into a global cooperation agreement for providing InnoCore’s proprietary SynBiosys® biodegradable polymer platform, this further can be used for the development of sustained release solutions for biologicals in injectable formulations.

The major players profiled in the injectable drug delivery market include Wilhelm Haselmeier GmbH & Co. KG, Owen Mumford Ltd., SHL Medical AG, Enable Injections, and Ypsomed AG.

Segmentation

The injectable drug delivery market has been analyzed through the following segments:

By Device Type

Needle-free injectors

Patch injectors

Auto injectors

Others

 

By Application

Disease Treatment

Research/Academic purposes

 

By Geography

North America

USA

Canada

Mexico

 

South America

Brazil

Argentina

Others

 

Europe

United Kingdom

Germany

France

Others

 

Middle East and Africa

Saudi Arabia

UAE

Israel

Others

 

Asia Pacific

China

India

Australia

South Korea

Others

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Currency

1.5. Assumptions

1.6. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY 

2.1. Research Design

2.2. Secondary Sources

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

4.1. Market Segmentation

4.2. Market Drivers

4.3. Market Restraints

4.4. Market Opportunities

4.5. Porter’s Five Force Analysis

4.5.1. Bargaining Power of Suppliers

4.5.2. Bargaining Power of Buyers

4.5.3. Threat of New Entrants

4.5.4. Threat of Substitutes

4.5.5. Competitive Rivalry in the Industry

4.6. Life Cycle Analysis - Regional Snapshot

4.7. Market Attractiveness

5. INJECTABLE DRUG DELIVERY MARKET BY DEVICE TYPE

5.1. Needle-free injectors

5.2. Patch injectors

5.3. Auto injectors

5.4. Others

6. INJECTABLE DRUG DELIVERY MARKET BY APPLICATION

6.1. Disease Treatment

6.2. Research/Academic purposes

7. INJECTABLE DRUG DELIVERY MARKET BY GEOGRAPHY

7.1. North America

7.1.1. USA

7.1.2. Canada

7.1.3. Mexico

7.2.  South America

7.2.1. Brazil

7.2.2. Argentina

7.2.3. Others

7.3. Europe

7.3.1. United Kingdom

7.3.2. Germany

7.3.3. France

7.3.4. Others

7.4. Middle East and Africa

7.4.1. Saudi Arabia

7.4.2. UAE

7.4.3. Israel

7.4.4. Others

7.5. Asia Pacific

7.5.1. China

7.5.2. India

7.5.3. Australia

7.5.4. South Korea

7.5.5. Others

8. COMPETITIVE INTELLIGENCE

8.1. Company Benchmarking and Analysis

8.2. Recent Investment and Deals

8.3. Strategies of Key Players

9. COMPANY PROFILES

9.1. Wilhelm Haselmeier GmbH & Co. KG

9.2. Owen Mumford Ltd.

9.3. SHL Medical AG

9.4. Enable Injections

9.5. Ypsomed AG

LIST OF FIGURES

LIST OF TABLES

Wilhelm Haselmeier GmbH & Co. KG

Owen Mumford Ltd.

SHL Medical AG

Enable Injections

Ypsomed AG